The European Medicines Agency (EMA) has set up an infrastructure to support the monitoring of the efficacy and safety of COVID-19 treatments and vaccines used in day-to-day clinical practice.nnAccording to the EMA, this is underpinned by three contracts for observational research that the agency has signed with academic and private partners over recent months, to be ready to effectively monitor vaccines in the real world as soon as they are authorised and support the safe and effective use of COVID-19 vaccines and medicines.
Experimental Ebola Treatments Still At Early Stage Of Development
EMA Pharmaceuticals News Full Screen View
Market Place
Share